November 2022 Vol 13, No 11
Connect with Us on Facebook, Attend a Facebook Live Session, Listen to a Podcast, or Check Out Our Blog
Experiences of Appointed Agents with Healthcare Power of Attorney for Lung Cancer Patients from a Nurse Navigator–Led Advance Care Planning Discussion
This qualitative descriptive study explored the benefits of ACP as an expanded role for the ONN by describing the perspectives of appointed healthcare power of attorney (HCPOA) agents for lung cancer patients who had their ACP discussion led by an ONN.
His new price controls might have killed Amgen’s breakthrough drug for lung cancer
The CATCH for November 2022 is awarded to Sara Sanchez, BSN, RN, a complex GI oncology nurse navigator with the Sarah Cannon Cancer Institute at Medical City Plano in Texas.
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
To assess OS at an updated cutoff with additional follow-up.
Phase 2 Study of Cemiplimab in Patients with Locally Advanced Basal-Cell Carcinoma After Hedgehog Inhibitor Therapy: Long-Term Follow-Up
Here, we present the long-term follow-up data at up to 40 months.
Page 1 of 2
Results 1 - 9 of 12
Results 1 - 9 of 12